{"url_path":"/sec/stok/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001193125-26-257394-index.html","accession_number":"0001193125-26-257394","cik":"0001623526","ticker":"STOK","issuer_name":"Stoke Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1623526/0001193125-26-257394-index.html","primary_entity_key":"0001623526","primary_entity_name":"Stoke Therapeutics, Inc."},"word_count":250,"has_tables":true,"body_markdown":"Item 5.07\n\nSubmission of Matters to a Vote of Security Holders.\n\nOn June 3, 2026, Stoke Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders, and the following proposals were adopted:\n\n \n\n1.\n\nElection of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal:\n\n \n\nNominees\n\n  \nShares For\n  \nShares Withheld\n  \nBroker Non-Votes\n\nG. Clare Kahn, Ph.D.\n\n  \n49,722,339\n  \n308,644\n  \n5,143,930\n\nAdrian Krainer, Ph.D.\n\n  \n36,531,612\n  \n13,499,371\n  \n5,143,930\n\nJulie Anne Smith\n\n  \n43,500,649\n  \n6,530,334\n  \n5,143,930\n\n \n\n2.\n\nRatification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:\n\n \n\nShares For\n\n  \nShares Against\n  \nShares Withheld/Abstaining\n\n55,121,163\n  \n2,036\n  \n51,714\n\n \n\n3.\n\nApproval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026:\n\n \n\nShares For\n\n  \nShares Against\n  \nShares Withheld/Abstaining\n  \nBroker Non-Votes\n\n36,436,275\n  \n13,565,293\n  \n29,415\n  \n5,143,930\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: June 4, 2026\n\n \n\nSTOKE THERAPEUTICS, INC.\n\nBy:\n \n\n/s/ Thomas E. Leggett\n\n \nThomas E. Leggett\n\n \nChief Financial Officer"}